综合治疗晚期肺癌生存期临床研究

Clinical study on life expectancy of advanced lung cancer patients by comprehensive treatment

目的探讨晚期肺癌综合治疗的生存期。方法2000～2004年将我院住院治疗的99例晚期肺癌病人分为2个治疗组,分别接受化疗54例和化疗诱导治疗后予以手术切除的15例两种治疗模式,另有30例对症支持治疗为对照组。结果两组治疗的患者中位生存期分别为13.3±18.1个月(无手术组)和21.9±19.2个月(有手术组),对照组患者中位生存期为7.1±9.0个月。手术加化疗组1年、2年、3年生存率80%、33%、20%。化疗组为37%、18%、14%。对症组为16%、10%、3%。结论对于晚期肺癌,化疗加手术切除综合治疗其生存率显著高于单纯手术治疗,也高于化疗和对症支持治疗。综合治疗仍是肺癌治疗的主旋律。

Objective To study life expectancy of advanced lung cancer by comprehensive treatment.Methods Ninety-nine advanced lung cancer patients were divided into three groups: one including 54 cases who were treated by chemotherapy, the second group including 15 patients who had operation after chemotherapy, and the third group of 30 patients with supporting-treatment were regarded as the controls. Results The mean life expectancy were 13.3±18.1 months (without operation), 21.9±19.2 months (with operation) and 7.1±9.0 months (control) respectively. The life expectancy rates for patients with operation and chemotherapy were 80%, 33% and 20% respectively in the first, second and the third year, similarly 37%,18% and 14% for the chemotherapy group and 16%,10% and3% for the control group.Conclusion The life expectancy of the late period of lung cancer with comprehensive treatment is much higher than that of the groups with simply operation or chemotherapy or supporting treatment. The comprehensive treatment is still a main treatment for lung cancer.